Niteesh K. Choudhry, M.D., Ph.D., is an internist and health services researcher whose work focuses on the development and evaluation of novel strategies to improve health care quality and reduce spending. He is an Associate Professor Medicine at Harvard Medical School, the founding Executive Director of the Center for Healthcare Delivery Sciences and an Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics, at Brigham and Women's Hospital, where he is also a practicing hospitalist.
Much of Dr. Choudhry’s current research deals with non-adherence to evidence-based medications, a problem that is estimated to cost almost $300 billion annually in the U.S. alone. He has led and is leading numerous clinical trials embedded in real-world health systems aimed at addressing this issue. He was the principal investigator of the Post-MI Free Rx and Event and Economic Evaluation (MI FREEE) trial, on the basis of which Aetna has changed their benefits to waive medication copayments for post-MI secondary prevention medications. He is the principal investigator of the National Heart Lung and Blood Institute-funded Study of a Telepharmacy Intervention for Chronic disease to Improve Treatment adherence (STIC 2 IT), the Robust Evaluation to Measure Improvements in Nonadherence from low-cost Devices (REMIND) trial, supported by CVS Health, the Targeted Adherence intervention to Reach Glycemic control with Insulin Therapy for Diabetes patients (TARGIT - Diabetes) study, funded by Sanofi, and the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) trial, funded by Astra Zeneca. In collaboration with the U.S. Behavioral Insights Team, the Center for Medicare and Medicaid Services and the National Vaccines Program Office, he is also Co-Principal Investigator of the Mail Outreach To Increase Vaccination Acceptance Through Engagement (MOTIVATE) trial.
A second focus of Dr. Choudhry’s work is predictive analytics: he seeks to identify which patients will ultimately become non-adherent to their prescribed therapies and why and when this will occur. He and his colleagues have applied and evaluated novel quantitative methods for clustering patients into longitudinal and dynamic adherence trajectories, shown their relationship to long-term clinical outcomes, and demonstrated the capacity to predict a patient’s membership in each of these adherence trajectories with great accuracy. In ongoing work, he and his colleagues are exploring the ability of novel data sources, such as retail purchasing information and electronic health record data, to improve the ability to predict future non-adherence.
Dr. Choudhry, who is Canadian by upbringing, attended McGill University, received his M.D. and completed his residency training in Internal Medicine at the University of Toronto and then served as Chief Medical Resident for the Toronto General and Toronto Western Hospitals. He earned his Ph.D. in Health Policy from Harvard University.
He has published over 175 peer-reviewed journals and has won numerous awards for research, teaching and mentoring. His work is supported by both public and private funders including the National Heart, Lung, and Blood Institute, the Agency for Healthcare Quality and Research, CVS Caremark, Aetna, the Robert Wood Johnson Foundation, the Commonwealth Fund, the Arnold Foundation, Merck, Sanofi, AstraZeneca and the Pharmaceutical Research and Manufacturers of America.
He serves on advisory committees for the Food and Drug Administration and the National Heart, Lung, and Blood Institute and is on the board of directors of the Alosa Foundation and Population Services International.